MedPage Today on MSN
Better Survival in Kidney Cancer After Stopping Therapy for Immune-Related AEs
DENVER -- Patients who discontinued treatment for advanced kidney cancer because of immune-related adverse events (irAEs) had ...
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease. Although late-stage kidney cancer generated ...
TTUHSC’s Thomas E. Hutson, D.O., Pharm.D., Ph.D., shared groundbreaking findings from the landmark CLEAR study Feb. 13-14 at the 2025 American Society of Clinical ...
(Reuters) - A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone ...
MedPage Today on MSN
Wins for Cabozantinib in Kidney Cancer Brain Mets, Aggressive Disease Subtype
Patients with kidney cancer brain metastases have a poor prognosis and have been excluded from most clinical trials of ...
Results from the phase II LenCabo trial show that lenvatinib plus everolimus significantly prolonged progression-free ...
MedPage Today on MSN
High-Fiber Diet May Boost Immunotherapy Activity in Advanced Kidney Cancer
D ENVER -- Patients with advanced kidney cancer treated with immune checkpoint inhibitors (ICIs) lived longer if they consumed a high-fiber diet, a small prospective study showed.
Dr. Joshua Sabai spoke with Dr. Chandler Park about the latest advances in kidney cancer, highlighting clinical trials that are shaping care for patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback